Document resource
At least one pupil in every classroom is at risk of food-induced anaphylaxis. Early intervention with adrenaline [epinephrine], by intramuscular injection or more recently the intranasal route, is critical in managing anaphylaxis. To facilitate this, adrenaline is available in many countries as an adrenaline autoinjector (AAI) device for self-administration by patients or caregivers/lay people including school staff. The UK Medicines and Healthcare products Regulatory Agency (MHRA) recommends people at risk of anaphylaxis have access to two adrenaline autoinjectors (AAIs) at all times.1 The MHRA advice is interpreted in different ways: some GPs will provide four AAIs (two for the patient, and two for school), while others will only prescribe two per patient. This variability is clearly described in an analysis by Turner and colleagues in this issue of Archives of Disease in Childhood.2